{"nctId":"NCT01461369","briefTitle":"Study of Diclofenac Capsules to Treat Osteoarthritis Pain","startDateStruct":{"date":"2011-10"},"conditions":["Osteoarthritis"],"count":305,"armGroups":[{"label":"Diclofenac Capsules 35 mg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Diclofenac"]},{"label":"Diclofenac Capsules 35 mg tid","type":"EXPERIMENTAL","interventionNames":["Drug: Diclofenac"]},{"label":"Placebo Capsule","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Diclofenac","otherNames":[]},{"name":"Diclofenac","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Primary diagnosis of Functional Class I-III OA of the hip or knee with documented osteoarthritis flare at baseline\n* Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain\n* Discontinued all analgesic therapy at Screening\n* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control\n\nExclusion Criteria:\n\n* History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDS, including diclofenac\n* Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip\n* Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease\n* Significant difficulties swallowing capsules or unable to tolerate oral medication\n* Previous participation in another clinical study of Diclofenac Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","description":"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing \"No Pain\" and 100 mm representing \"Extreme Pain\".\n\nThe WOMAC pain subscale score difference is calculated as the WOMAC pain subscale score assessed at Week 12 minus the WOMAC pain subscale score assessed at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.04","spread":"2.905"},{"groupId":"OG001","value":"-44.14","spread":"3.070"},{"groupId":"OG002","value":"-32.46","spread":"2.937"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","description":"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing \"No Pain\" and 100 mm representing \"Extreme Pain\".\n\nThe WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 2 minus the WOMAC pain subscale score assessed at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.40","spread":"2.742"},{"groupId":"OG001","value":"-37.42","spread":"2.907"},{"groupId":"OG002","value":"-21.60","spread":"2.787"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","description":"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing \"No Pain\" and 100 mm representing \"Extreme Pain\".\n\nThe WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 6 minus the WOMAC pain subscale score assessed at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.64","spread":"2.889"},{"groupId":"OG001","value":"-43.51","spread":"3.051"},{"groupId":"OG002","value":"-31.08","spread":"2.922"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","description":"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing \"No Pain\" and 100 mm representing \"Extreme Pain\".\n\nThe WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Weeks 2, 6, and 12 minus the average of the WOMAC pain subscale score assessed at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.62","spread":"2.633"},{"groupId":"OG001","value":"-41.38","spread":"2.796"},{"groupId":"OG002","value":"-28.14","spread":"2.647"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total (Composite) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.","description":"Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total (composite) WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing \"No Pain, Stiffness, or Difficulty\" and 100 mm representing \"Extreme Pain, Stiffness, and Difficulty\".\n\nThe total (composite) WOMAC score difference was calculated as the total (composite) WOMAC score assessed at Weeks 2, 6, and 12 minus the total (composite) WOMAC score assessed at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.25","spread":"2.632"},{"groupId":"OG001","value":"-35.86","spread":"2.798"},{"groupId":"OG002","value":"-23.22","spread":"2.656"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale.","description":"The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing \"No Pain\" and 100 mm representing \"Worst Pain Imaginable\".\n\nThe VAS pain intensity difference is calculated as the average of the VAS pain intensity scores at Weeks 2, 6, and 12 minus the VAS pain intensity at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.41","spread":"2.670"},{"groupId":"OG001","value":"-41.33","spread":"2.830"},{"groupId":"OG002","value":"-30.95","spread":"2.690"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":104},"commonTop":["Nausea","Diarrhea","Upper respiratory tract infection","Headache"]}}}